Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

Anna Żurawska; Anne H. Cross; Katarzyna Rzeszutek; Agnieszka Rogozińska-Zawiślak; Krzysztof Selmaj

doi:10.1001/jamaneurol.2026.0548

April 6, 2026JAMA Neurology

Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to explore the occurrence of interstitial lung disease in multiple sclerosis patients treated with ocrelizumab.
Case series involving 6 patients with multiple sclerosis
Long-term treatment with ocrelizumab
Observation of respiratory symptoms
Interstitial lung disease was identified in 6 patients
All patients were on long-term ocrelizumab therapy
Symptoms involved respiratory distress and imaging findings

Implication

Case series identifies interstitial lung disease in multiple sclerosis patients on ocrelizumab, suggesting monitoring is necessary.

Abstract

This case series describes 6 cases of interstitial lung disease among patients with multiple sclerosis receiving long-term treatment with ocrelizumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Żurawska et al. (2026) studied this question.

synapsesocial.com/papers/69d5f0ee74eaea4b11a7a60e https://doi.org/10.1001/jamaneurol.2026.0548

View at Publisher

Ask AI

Bookmark

Share

Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

Key Points

Implication

Abstract

Discussion

Cite This Study

Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading